Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism
1 finding from 1 review
Change in serum androgen levels · women with hirsutism
1 finding from 1 review
Change in BMI · women with hirsutism
1 finding from 1 review
Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) showed no clear difference in recurrence compared with placebo (same regimen) (low certainty).
1 finding from 1 review
Percentage of lesions cured after the end of treatment · patients with Old World cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with complete cure · patients with Old World cutaneous leishmaniasis
It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes percentage of participants with complete cure compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects Mild abdominal pain and nausea Adverse effects Mild abnormal liver function · patients with Old World cutaneous leishmaniasis
It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes adverse effects Mild abdominal pain and nausea Adverse effects Mild… compared with placebo (very low certainty).
1 finding from 1 review
Time to complete healing · patients with Old World cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microbiological or histopathological cure of skin lesions · patients with Old World cutaneous leishmaniasis
It is very uncertain whether itraconazole (200 mg for 6 to 8 weeks) changes microbiological or histopathological cure of skin lesions compared with placebo (very low certainty).
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Thermotherapy one session (at 50 ºC for 30 seconds) leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg Sb5/kg/day (high certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review